Metagenomi Therapeutics (MGX) Revenue (2023 - 2026)
Metagenomi Therapeutics (MGX) posted quarterly Revenue of $1.2 million for Q1 2026, down 69.76% year-over-year from $4.1 million in Q1 2025, and down 68.09% quarter-over-quarter from $3.9 million in Q4 2025.
Metagenomi Therapeutics (MGX) Revenue (2023 - 2026) Analysis & Trends
Metagenomi Therapeutics (MGX) has reported Revenue for 4 consecutive years, with $1.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Revenue fell 69.76% year-over-year to $1.2 million; the TTM figure through Mar 2026 stood at $22.3 million (down 50.66% YoY), while the FY2025 annual figure was $25.2 million, down 51.79% from the prior year.
- Revenue fell to $1.2 million in Q1 2026 per MGX's latest filing, from $3.9 million in the prior quarter.
- Across five years, Revenue topped out at $20.0 million in Q2 2024 and bottomed at $1.2 million in Q1 2026.
- Historically, Revenue has averaged $9.5 million across 4 years, with a median of $9.6 million in 2024.
- Annual changes were most pronounced in 2024 — Revenue soared 76.48% — and 2026, when it slumped 69.76%.
- Metagenomi Therapeutics' Revenue stood at $12.4 million in 2023, then retreated by 22.46% to $9.6 million in 2024, then tumbled by 59.32% to $3.9 million in 2025, then tumbled by 68.09% to $1.2 million in 2026.
- Business Quant data shows MGX's Revenue at $1.2 million in Q1 2026, $3.9 million in Q4 2025, and $8.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 145.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.71 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.29 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 425.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 674.14 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 1.06 Bn |
| 10 | Metagenomi Therapeutics | 45.38 Mn | 45.38 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.25 Mn |
| Dec 31, 2025 | 3.91 Mn |
| Sep 30, 2025 | 8.66 Mn |
| Jun 30, 2025 | 8.51 Mn |
| Mar 31, 2025 | 4.13 Mn |
| Dec 31, 2024 | 9.61 Mn |
| Sep 30, 2024 | 11.51 Mn |
| Jun 30, 2024 | 20.01 Mn |
| Mar 31, 2024 | 11.16 Mn |
| Dec 31, 2023 | 12.40 Mn |
| Sep 30, 2023 | 12.36 Mn |
| Jun 30, 2023 | 11.34 Mn |
| Mar 31, 2023 | 8.66 Mn |